AGGRENOX has an established safety profile2

Incidence of Headache, GI Events, and Bleeding in ESPS 2 (%)*

AGGRENOX BID
n=1650
Aspirin (25 mg BID)
n=1649
Placebo
n=1649
Headache 39% 34% 33%
GI Events
Dyspepsia 18% 18% 17%
Abdominal pain 18% 16% 14%
Nausea 16% 13% 14%
Diarrhea 13% 7% 10%
Vomiting 8% 6% 7%
Bleeding
Hemorrhage NOS 3% 3% 1%
Epistaxis 2% 3% 2%
Purpura 1% 1% 0%

*Bleeding was most commonly reported (in descending order) as epistaxis, “other” sites, proctorrhagia, melena, hematuria, hematemesis, and purpura.4

GI=gastrointestinal; NOS=not otherwise specified.

;